Previously published trials on PSMA RLT, including a phase III clinical trial, have confirmed promising response rates and low toxicity in patients with PSMA-positive metastatic castration-resistant prostate cancer, especially when added to the standard care (17–20). This evidence concerns the gene FOLH1 and prostate carcinoma.